Gene therapy progress and prospects: Adenoviral vectors

Gene Therapy

Volumn 10, Issue 14, 2003, Pages 1135-1141

  St George, J A ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Adenovirus; Targeting; Toxicity

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFLAMMATORY AGENT; BUDESONIDE; CANCER VACCINE; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CELL DIVISION; CELL TYPE; CENTRAL NERVOUS SYSTEM; CLINICAL PROTOCOL; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HEPATIC ARTERY; HUMAN; IMMUNE RESPONSE; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE;

ADENOVIRIDAE; ANIMALS; FORECASTING; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, ANIMAL; PRIMATES; TRANSDUCTION, GENETIC; TRANSGENES;

ADENOVIRIDAE; DNA VIRUSES;

EID: 0041808932     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302071     Document Type: Review

References (63)

1. Makinen K et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-133.
2. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther 2002; 13: 3-13.
3. Zhang Y et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001; 3: 697-707.
4. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther 2002; 13: 129-141.
5. Borgland SL et al. Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB. J Virol 2000; 74: 3941-3947.
6. Cichon G et al. Complement activation by recombinant adenoviruses. Gene Therapy 2001; 8: 1794-1800.
7. Morelli AE et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol 2000; 74: 9617-9628.
8. Schnell MA et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001; 3(Part 1): 708-722.
9. Morral N et al. Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 2002; 13: 143-154.
10. Raper SE et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-175.
11. Eggerman TL, Mondoro TH, Lozier JN, Vostal JG. Adenoviral vectors do not induce, inhibit, or potentiate human platelet aggregation. Hum Gene Ther 2002; 13: 125-128.
12. Lozier JN et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. Hum Gene Ther 2002; 13: 113-124.
13. Crystal RG et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther 2002; 13: 65-100.
14. Harvey BG et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15-63.
15. Ben Gary H et al. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther 2002; 6: 287-297.
16. Kolb M et al. Budesonide enhances repeated gene transfer and expression in the lung with adenoviral vectors. Am J Respir Crit Care Med 2001; 164: 866-872.
17. Nemerow GR. Adenoviral vectors - new insights. Trends Microbiol 2000; 8: 391-394.
18. Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nat Med 2003; 9: 135-139.
19. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther 2000; 1(Part 1): 391-405.
20. Ostapchuk P, Hearing P. Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E. J Virol 2001; 75: 45-51.
21. Havenga MJ et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002; 76: 4612-4620.
22. Su EJ et al. A genetically modified adenoviral vector exhibits enhanced gene transfer of human smooth muscle cells. J Vasc Res 2001; 38: 471-478.
23. Loser P et al. Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle. Gene Therapy 2000; 7: 1491-1498.
24. Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargeting of adenovirus: novel strategy employing 'deknobbing' of the fiber. J Virol 2001; 75: 7280-7289.
25. van Beusechem VW et al. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Therapy 2000; 7: 1940-1946.
26. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002; 1575: 1-14.
27. Nicklin SA et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001; 4: 534-542.
28. Xia H, Anderson B, Mao Q, Davidson BL. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol 2000; 74: 11359-11366.
29. Bakker AC et al. A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Therapy 2001; 8: 1785-1793.
30. Biermann V et al. Targeting of high-capacity adenoviral vectors. Hum Gene Ther 2001; 12: 1757-1769.
31. Levy RJ et al. Localized adenovirus gene delivery using antiviral IgG complexation. Gene Therapy 2001; 8: 659-667.
32. Israel BF et al. Enhancement of adenovirus vector entry into CD70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody. J Virol 2001; 75: 5215-5221.
33. Nettelbeck DM et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001; 3: 882-891.
34. Barnett BG, Tillman BW, Curiel DT, Douglas JT. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol Ther 2002; 6: 377-385.
35. Hartigan-O'Connor D et al. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001; 4: 525-533.
36. Smith T et al. In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther 2002; 5: 770-779.
37. Dechecchi MC et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
38. De Geest B et al. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 2000; 11: 101-112.
39. Gerdes CA, Castro MG, Lowenstein PR. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo. Mol Ther 2000; 2: 330-338.
40. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002; 99: 3923-3930.
41. Ding EY et al. Long-term efficacy after [E1-, polymerase-] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice. Hum Gene Ther 2001; 12: 955-965.
42. Andrews JL et al. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther 2001; 3: 329-336.
43. Braithwaite AW, Russell IA. Induction of cell death by adenoviruses. Apoptosis 2001; 6: 359-370.
44. Tauber B, Dobner T. Molecular regulation and biological function of adenovirus early genes: the E4 ORFs. Gene 2001; 278: 1-23.
45. Zhou H, Beaudet AL. A new vector system with inducible E2a cell line for production of higher titer and safer adenoviral vectors. Virology 2000; 275: 348-357.
46. Kochanek S, Schiedner G, Volpers C. High-capacity 'gutless' adenoviral vectors. Curr Opin Mol Ther 2001; 3: 454-463.
47. Umana P et al. Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 2001; 19: 582-585.
48. Ng P et al. Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther 2001; 3(Part 1): 809-815.
49. Reddy PS et al. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector. Mol Ther 2002; 5: 63-73.
50. Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA. A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Therapy 2001; 8: 846-854.
51. Sakhuja K et al. Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 2003; 14: 243-254.
52. Kim IH et al. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001; 98: 13282-13287.
53. Chen P, Kovesdi I, Bruder JT. Effective repeat administration with adenovirus vectors to the muscle. Gene Therapy 2000; 7: 587-595.
54. Buller RE et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
55. Moffatt S, Hays J, HogenEsch H, Mittal SK. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 2000; 272: 159-167.
56. Rahman A et al. Specific depletion of human anti-adenovirus antibodies facilitates transduction in an in vivo model for systemic gene therapy. Mol Ther 2001; 3(Part 1): 768-778.
57. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 'Stealth' adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 2001; 75: 4792-4801.
58. Fisher KD et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Therapy 2001; 8: 341-348.
59. Yotnda P et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002; 5: 233-241.
60. Ziller C, Stoeckel F, Boon L, Haegel-Kronenberger H. Transient blocking of both B7.1 (CD80) and B7.2 (CD86) in addition to CD40-CD40L interaction fully abrogates the immune response following systemic injection of adenovirus vector. Gene Therapy 2002; 9: 537-546.
61. Jiang Z, Feingold E, Kochanek S, Clemens PR. Systemic delivery of a high-capacity adenoviral vector expressing mouse CTLA4Ig improves skeletal muscle gene therapy. Mol Ther 2002; 6: 369-376.
62. Jiang ZL et al. Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscle. Mol Ther 2001; 3: 892-900.
63. Thummala NR et al. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine-diphosphoglucuronateglucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Therapy 2002; 9: 981-990.